Several vascular disorders such as aberrant angiogenesis, atherosclerosis and pulmonary hypertension have been linked to dysfunctional BMP signaling. As vascular hyperpermeability via distortion of endothelial cell adherens junctions is a common feature of these diseases, the role of BMPs in this process has not been investigated yet. 
Introduction
Endothelial cells line the lumen of blood vessels and form a semi-permeable monolayer that controls blood-tissue exchange of fluids, plasma proteins and cells. Thus, the integrity of the endothelial barrier is essential for physiological tissue homeostasis and hyperpermeability is involved in the progression of several pathological conditions, including inflammation, atherosclerosis and cancer (Davignon and Ganz, 2004; Weis and Cheresh, 2005) .
Vascular permeability is mainly regulated by two different mechanisms: transcellular and paracellular permeability. During transcytosis, macromolecules pass individual endothelial cells via specialized vesicles containing caveolin-1 (Bauer et al., 2005) or transmembrane channels formed by fused vesiculo-vacuolar organelles (VVOs) (Dvorak et al., 1996) . Paracellular permeability is mediated by the dynamic opening of inter-endothelial cell junctions that allow large proteins and cells to enter the surrounding tissue. Alterations of cell-cell adhesion, mainly mediated by tight (TJs) and adherens junctions (AJs), is a hallmark of paracellular permeability (Goddard and Iruela-Arispe, 2013) . TJs mediate intercellular adhesion by complex formation of several members of the claudin, occludin and junctional adhesion molecule (JAM) protein families and have been implicated in the regulation of the blood-brain barrier (Luissint et al., 2012) . Vascular hyperpermeability in the microvasculature has been repeatedly linked to changes in the AJ architecture. AJs are mainly formed by calcium-dependent interactions of vascular endothelial cadherins (VE-Cadherins, also known as cadherin 5 or CD144) between neighbouring cells. VE-Cadherin is a single-span transmembrane protein exclusively expressed by endothelial cells and its extracellular domain forms homomeric dimers with VE-Cadherin molecules of adjacent cells (Bravi et al., 2014) .
The cytoplasmic domain of VE-Cadherin interacts with members of the actin-binding catenin family and thus links VE-Cadherin to the cytoskeleton (Lampugnani et al., 1995; Iyer et al., 2004) . VE-Cadherin is the main component of endothelial AJs and homophilic VE-Cadherin interactions have been reported to regulate vascular permeability. Among those regulatory mechanisms, internalization and tyrosine phosphorylation of VE-Cadherin are strongly associated with impaired barrier function. It has been shown that vascular endothelial growth factor (VEGF), a potent permeability-inducing agent, triggers VE-Cadherin internalization (Gavard and Gutkind, 2006) . Internalized VE-Cadherin enters endosomal compartments and is either recycled to the plasma membrane or degraded (Xiao et al., 2003a; Xiao et al., 2005) .
Hence, the promotion of VE-Cadherin internalization controls permeability in a reversible manner. Besides, several studies demonstrated that other permeabilizing agents, such as tumor necrosis factor α (TNF-α) (Angelini et al., 2006) or histamine (Andriopoulou et al., 1999) , modulate AJ stability by tyrosine phosphorylation of VE-Cadherin. It was shown that members of the Src kinase family phosphorylate VE- Cadherin (Eliceiri et al., 1999) and Tyr685 of VE-Cadherin was identified as a unique target site for Src in vitro (Wallez et al., 2007) . Recently, it has been reported that phosphorylation at Tyr685 controls vascular permeability in vivo, while phosphorylation at Tyr731 regulates leukocyte diapedesis (Wessel et al., 2014) . This highlights that modifications of VE-Cadherin allow diverse alterations of the AJ architecture and thereby dynamic disruptions of the endothelial cell barrier. This diversity is needed considering that plasma protein and cell extravasation requires openings of different sizes.
Besides controlling the endothelial barrier function, VE-Cadherin has been implicated in the regulation of growth factor signaling. VE-Cadherin interacts with the VEGFR2 and VECadherin clusters retain VEGFR2 at the plasma membrane (Lampugnani et al., 2006) .
Moreover, VE-Cadherin has been implicated in the regulation of transforming growth factor β (TGF-β)-mediated inhibition of endothelial cell proliferation and migration (Rudini et al., 2008) . It has been shown that VE-Cadherin interacts with the TGF-β type I receptors activin receptor-like kinase 1 and 5 (ALK1 and ALK5) as well as the type II receptor (TGFβRII) and functions as a positive regulator of TGF-β signal transduction.
Bone morphogenetic proteins (BMPs) belong to the TGF-β family of secreted growth factors that comprises more than 30 structurally related ligands, which are tissue-specifically expressed and regulated by natural antagonists. BMPs bind to transmembrane serine/threonine kinase receptors and the signal is transduced into the cytosol via a heteromeric receptor complex of type I and type II receptors. Receptor complex activation results in induction of distinct intracellular signaling cascades, the canonical Smad-and nonSmad pathways. Once receptor-regulated Smads (R-Smads, Smad1/5/8) are activated upon phosphorylation by a type I receptor, they form a complex with the common-mediator Smad (co-Smad, Smad4) to function as transcription factors and together with transcriptional coactivators and co-repressors regulate the expression of BMP target genes, such as ID1 (Sieber et al., 2009) .
BMP signal transduction is implicated in the regulation of physiological as well as pathological processes of the endothelium. Interestingly, altered BMP signaling was observed during acute inflammation, atherosclerosis and metastasis (Cai et al., 2012; Dyer et al., 2014) .
A common hallmark of these diseases is vascular hyperpermeability as plasma proteins or cells enter the surrounding tissue and lead to formation of edema, plaques or metastases respectively (Kumar et al., 2009; Reymond et al., 2013) . However, the precise function of BMP signaling in the regulation of endothelial cell permeability remains elusive. Therefore, we investigated whether BMP signal transduction controls permeability of human umbilical vein endothelial cell (HUVEC) monolayers and demonstrate that BMP6 induces hyperpermeability by promotion of VE-Cadherin internalization as well as Src-mediated tyrosine phosphorylation. Furthermore, we identify VE-Cadherin as a novel regulator of vascular BMP signal transduction and show that VE-Cadherin physically associates with the BMP type I receptor activin receptor-like kinase 2 (ALK2) and the BMP type II receptor (BMPRII) in a BMP6-dependent manner and that it stabilizes receptor complex formation.
Results

BMP6 induces hyperpermeability and disruption of AJ architecture
To assess the effects of BMP signaling on vascular permeability, we measured solute flux across an endothelial cell monolayer. HUVECs were seeded onto collagen-coated transwellinserts and stimulated with BMP6 or VEGF-165 for 24 hours. Subsequently, flux of high molecular weight FITC-Dextran across the monolayer was measured. We found that BMP6 stimulation lead to a 2.7-fold increase in paracellular permeability, similar to the potent permeability-inducing growth factor VEGF-165 (Fig. 1A) . When a pharmacological BMP type I receptor kinase inhibitor (LDN-193189) (Cuny et al., 2008) was administered 60 minutes before BMP6 stimulation, BMP6 mediated permeability was inhibited suggesting active BMPRI kinase being important for this process. Thus, we hypothesized that BMP6-induced permeability required signal transduction downstream of the BMP receptors. A costimulation with BMP6 and VEGF-165 showed no synergistic effects. These data suggested that BMP signaling specifically induced permeability of an endothelial cell monolayer.
We next addressed the kinetics of BMP-induced permeability measuring transendothelial electrical resistance (TEER) changes. Electrical resistance decreased upon BMP6 treatment in a time-and dose-dependent manner ( Fig. 1B; supplementary material, Fig. S1 ). A significant reduction (p < 0.05) was detected as early as two hours after stimulation and progressed over time resulting in a 68 ± 8% (mean ± s.d.) reduction after 24 hours compared to untreated control cells (Fig. 1B) . Treatment of HUVEC monolayer with VEGF-165 showed similar effects (68 ± 4%, mean ± s.d.). Thus, both methods of choice demonstrated a strong increase in permeability upon BMP6 stimulation. 
BMP6 triggers internalization of VE-Cadherin
An increase in vascular permeability and concomitant disruptions of cell-cell contacts have been linked to internalization into sub-cellular compartments and subsequent recycling or degradation of VE-Cadherin (Gavard and Gutkind, 2006) . Therefore, we determined whether BMP stimulation modulates VE-Cadherin endocytosis rates. To address this question, we labeled VE-Cadherin on sparse and confluent HUVEC cultures using a specific monoclonal antibody (BV6) targeting an extracellular epitope of VE- Cadherin (Corada et al., 2001) . The cells showed a cell-surface staining that was sensitive to acid wash ( Fig. 2A; supplementary material, Fig. S2A ). Although the BV6 antibody was described to increase endothelial cell permeability, we did not detect significant amounts of intracellular VE-Cadherin vesicles in control cells ( Fig. 2A) . This suggests that the antibody exerts its effects by inhibition of VECadherin clustering at 37°C. However, upon 60 minutes of BMP6 treatment, an acid-resistant intracellular VE-Cadherin staining was observed in sparse HUVECs comparable to VEGF-165 stimulation conditions. Quantification of labeled VE-Cadherin uptake normalized to untreated control cells revealed similar effects for BMP6 and VEGF-165 treatment (Fig. 2B ).
Upon four hours of BMP6 or VEGF-165 treatment, similar observations were made in confluent HUVECs (supplementary material, Fig. S2 ). From this we conclude that BMP6 induces VE-Cadherin internalization.
To further investigate BMP6-induced internalization of VE-Cadherin, we biotinylated cell surface proteins using Sulfo-NHS-SS biotin (Gabriel et al., 2009 ). Subsequently, we allowed endocytosis for 60 minutes, stripped remaining extracellular biotin and measured levels of biotinylated, internalized VE-Cadherin. Removal of biotinylated, cell-surface VE-Cadherin was very efficient as demonstrated by stripping controls (stripping efficiency: 92 ± 7%, mean ± s.d.) (Fig. 2C ). Control cells exhibited relatively low levels of internalized VE-Cadherin (18% of total VE-Cadherin) and levels were increased upon BMP6 stimulation (50% of total VE-Cadherin) in a dose-dependent manner. Quantifications showed that addition of 10 nM BMP6 resulted in a 1.4-fold increase in biotinylated internalized VE-Cadherin compared to untreated control cells, while 30 nM BMP6 lead to a 2.2-fold increase (Fig. 2D) . Again, similar effects were observed upon 2 nM VEGF-165 treatment (1.8-fold). These data showed that addition of BMP6 to endothelial cells resulted in an increased VE-Cadherin internalization.
BMP6 induces phosphorylation of VE-Cadherin at Tyr685 by activating c-Src
Besides its internalization, post-translational modifications of VE-Cadherin have been shown to regulate vascular permeability. Recently, it has been demonstrated that phosphorylation of VE-Cadherin at Tyr685 controls the opening of endothelial cell junctions in vivo (Wessel et al., 2014) . Hence, we analyzed whether BMP signal transduction alters the phosphorylation status of VE-Cadherin. To investigate this, we immunoprecipitated (IP) VE-Cadherin from BMP6 stimulated or untreated HUVECs and analyzed the levels of VE-Cadherin phosphorylation at Tyr685 using a phospho-specific antibody. Upon 30 minutes of BMP6 treatment, we observed an increase in levels of phosphorylated VE-Cadherin (Fig. 3A) .
Quantifications yielded a 6-fold increase in the levels of phosphorylated VE-Cadherin ( Fig.   3B ). Thus, we concluded that BMP6 induced phosphorylation of VE-Cadherin at Tyr685.
Next, we investigated the molecular mechanism underlying this phosphorylation event. It has been shown that c-Src specifically phosphorylates VE-Cadherin at Tyr685 upon VEGF-165 stimulation in vitro (Wallez et al., 2007 ). Therefore, we tested whether BMP6 is able to A similar approach demonstrated an association between the high affinity BMPRI for BMP-6, ALK2 and c-Src upon overexpression in HEK293T cells (Fig. 3F ). These findings suggested that c-Src interacts with the BMP receptor complex and its activity is regulated by BMP signal transduction.
To further dismantle the interplay of BMP signaling, we performed knock-down experiments using siRNAs targeting ALK2, the high affinity receptor for BMP6, or SRC (supplementary material, Fig. S3B ). We demonstrated that upon BMP6 treatment, VE-Cadherin was phosphorylated at Tyr685 and this phosphorylation was partially abrogated by knock-down of ALK2 (53% reduction) or SRC (85% reduction) (Fig. 3G) . Similar, but less pronounced results were obtained with respect to c-Src phosphorylation at Tyr416 (ALK2 knock-down: 30% reduction; SRC knock-down: 67% reduction). Phosphorylation of Smad1/5 was completely abrogated by knock-down of ALK2, however unaffected in SRC knock-down conditions. Furthermore, using small molecule inhibitors targeting either ALK2 kinase (K02288) (Sanvitale et al., 2013) Taken together, our findings suggest that BMP6-induced permeability requires ALK2 and, at least partly, c-Src.
VE-Cadherin facilitates BMP signal transduction
As we demonstrated an effect of BMP signal transduction on VE-Cadherin internalization and As levels of phosphorylated Smad1/5 were decreased in VE-Cadherin knock-down conditions, we analyzed whether Smad1/5-dependent ID1 expression was altered as well (Korchynskyi and ten Dijke, 2002) . Therefore, we treated HUVECs with si-scr or si-CDH5, stimulated with BMP6 for 60 minutes and subsequently determined ID1 mRNA expression levels using quantitative RT-PCR. We observed an increase in ID1 expression levels between BMP6 treated and unstimulated control cells, that was significantly decreased by 28% (p = 0.042) upon treatment with si-CDH5 (Fig. 4C) . Treatment of HUVECs with si-CDH5 resulted in an 87 ± 2% (mean ± s.d.) reduction of CDH5 mRNA (Fig. 4D) . These data showed that the transcriptional activity of Smad1/5 was reduced upon knock-down of VE-Cadherin.
The major function of VE-Cadherin is to form clusters in a trans-homophilic manner between neighbouring cells and to facilitate the formation of cell-cell junctions. Hence, we examined whether proper clustering of VE-Cadherin at AJs is needed for endothelial BMP6 signaling.
The BV6 antibody has been described to block homophilic interactions and dismantle VE- 
VE-Cadherin associates with the BMP receptor complex
We showed that VE-Cadherin regulated BMP6-induced phosphorylation of Smad1/5 and downstream transcriptional activity. It has been previously reported that VE-Cadherin forms complexes with structurally related TGF-β receptors (Rudini et al., 2008 ) and thus we hypothesized that VE-Cadherin might also interact with the related BMP receptors. To test this in intact cells, we made use of an in situ proximity ligation assay (PLA). HUVECs were either stimulated with BMP6 for 60 minutes or left untreated. Subsequently, cells were fixed and probed with antibodies targeting intracellular epitopes of either ALK2 or BMPRII in combination with VE-Cadherin. Heteromers were visualized by proximity-dependent ligation of species-specific, oligonucleotide-conjugated secondary antibodies and followed by incubation with a fluorescent probe. While cells non-treated with ligand only have few ALK2/VE-Cadherin as well BMPRII/VE-Cadherin heteromers (Fig. 5A ), cells exposed to BMP6 showed a higher number of heteromers for both ALK2/VE-Cadherin (2-fold, p = 0.004) and BMPRII/VE-Cadherin (2.3-fold , p ≤ 0.001) heteromers (Fig. 5B) . This suggested that VE-Cadherin physically associated with BMP type I and type II receptors in a liganddependent manner.
To confirm this interaction, we immunoprecipitated VE-Cadherin from confluent HUVECs stimulated with BMP6 for 60 minutes or left untreated and analyzed for associated BMPRII.
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Complex formation between VE-Cadherin and BMPRII was already detectable in control HUVECs, but the interaction increased upon ligand addition (Fig. 5C ). These VECadherin/BMPR complexes were further validated by overexpression of HA-tagged BMPRII or ALK2 in combination with VE-Cadherin in HEK293T cells followed by immunoprecipitation of VE-Cadherin ( Fig. 5D and E) .
BMP signal transduction is initiated upon ligand-induced activation of the heteromeric BMP type I and type II receptor complex. As VE-Cadherin interacted with both receptor types in a ligand-dependent fashion and positively regulated downstream signaling, we hypothesized that VE-Cadherin is needed for proper BMP receptor complex assembly. To address this question, we overexpressed HA-tagged ALK2 and Myc-tagged BMPRII in the absence or presence of co-expressed VE-Cadherin in HEK293T cells and stimulated with BMP6 for 45 minutes. Subsequently, BMPRII-Myc was immunoprecipitated and protein levels of associated ALK2-HA and VE-Cadherin were determined. In the absence of VE-Cadherin, a low degree of receptor oligomerization was observed in BMP6-treated cells (Fig. 5F , lane 1 + 2). This interaction was remarkably increased when VE-Cadherin was co-expressed and ligand-dependent complex formation between ALK2, BMPRII and VE-Cadherin was detected (Fig. 5F, lane 4) . These data demonstrated that VE-Cadherin physically associated with ALK2 and BMPRII in a ligand-dependent manner in endothelial cells and stabilized BMP receptor complex formation.
Discussion
Vascular BMP signaling regulates physiological as well as pathological processes in the endothelium, yet a detailed molecular analysis of its influence on vascular permeability is still missing. Here, we provide evidence that BMP6 increases permeability in vitro and unravel a hitherto undescribed regulatory mechanism of vascular BMP signal transduction involving VE-Cadherin.
We measured solute flux and electrical resistance across a HUVEC monolayer to assess alterations in permeability and showed that BMP6 induced hyperpermeability similar to VEGF in a time-and dose-dependent manner. Pharmacological inhibition of the BMP6 type I receptor ALK2 demonstrated that this process required activation of the BMP receptor complex. These findings are in line with a recent study showing that BMP2 induces permeability of retinal endothelial cells (Hussein et al., 2014) . BMP2 was up-regulated in human and murine diabetic retinas and promoted permeability in a time-dependent manner.
Moreover, BMP2-induced hyperpermeability was also reported in lung epithelial cells (Helbing et al., 2013) . BMP2 was up-regulated in injured lung epithelium and caused increased solute permeability of cultured bronchial epithelial cells via activation of Smad1/5-Id1 signaling and down-regulation of E-Cadherin. The authors conclude that excessive BMP activity is involved in disruption of epithelial barrier function after lung injury. This assumption is consistent with other published studies that relate BMP signaling to disturbed barrier function. During acute inflammation, increased vascular permeability is one of the first events in order for plasma proteins, fluids and immune cells to reach the injured tissue.
Several reports indicate that BMP signaling is activated during inflammation and atherosclerosis and increased monocyte adhesion to endothelial cells has been observed upon BMP treatment Sorescu et al., 2003; Sorescu et al., 2004; Helbing et al., 2011; Derwall et al., 2012; Lee et al., 2012) . Another process that involves opening of the endothelial barrier is metastasis. During metastasis, disseminated cancer cells extravasate from the bloodstream to invade surrounding tissues and organs. It has been repeatedly described that BMPs enhance invasiveness of cancer cells in vitro and in vivo (Thawani et al., 2010) and BMP6 expression correlated with the metastatic potential of prostate cancer Whether VE-Cadherin contains serine/threonine residues that can be phosphorylated by the BMP receptors and whether these modifications initiate β-arrestin-mediated internalization to control vascular permeability similar to VEGF, remains unexplained at present.
Another mechanism that impairs endothelial barrier function is the tyrosine phosphorylation of VE-Cadherin, which promotes the remodeling of AJs. It has been described that multiple permeability-increasing agents, such as VEGF (Esser et al., 1998) (Sidibe et al., 2014; Wessel et al., 2014) . Thus, we addressed whether BMP signaling induces phosphorylation of VE-Cadherin and showed that upon BMP6 stimulation of HUVECs, VE-Cadherin was phosphorylated at Tyr685. A peptide mapping approach on the cytoplasmic domain of VE-Cadherin indicated that Tyr685 is specifically phosphorylated by c-Src (Wallez et al., 2007) . This finding is in line with several other studies that demonstrate an involvement of c-Src in VEGF-induced vascular permeability (Eliceiri et al., 1999; Gavard et al., 2008; Ha et al., 2008) . Here, we provide evidence for a BMP6-induced activation of c-Src in an ALK2 kinase-dependent manner in HUVECs. We show that ALK2 and c-Src were required for phosphorylation of VE-Cadherin at Tyr685. Moreover, we demonstrate a physical interaction of c-Src and ALK2 as well as BMPRII and that c-Src becomes activated upon receptor complex formation and in turn phosphorylates downstream targets at specific tyrosine residues. These observations are in contrast to a recent study demonstrating that mice carrying heterozygous null Bmpr2 mutations in pulmonary endothelial cells show constitutive activation of Src kinase and that this effect can be reversed by BMP2 stimulation (Prewitt et al., 2015) . Furthermore, BMP signaling was shown to inhibit Src activation in pulmonary smooth muscle cells, but large differences in inhibition potential were seen between different BMPs and BMP7, member of the same BMP subgroup as BMP6, only had a mild effect on Src kinase inhibition (Wong et al., 2005) . The authors also show a BMPRII-Src interaction using a yeast-two-hybrid approach and overexpression in HEK293T, yet this interaction has so far not been reproduced in any other cell type. Hence, these studies and our findings strongly indicate that BMP- Besides describing its influence on endothelial cell permeability, we report a novel regulatory mechanism of vascular BMP signal transduction by VE-Cadherin. We showed that VECadherin knock-down in HUVECs decreased BMP signaling activity and that proper VECadherin clustering at endothelial cell-cell junctions was required for efficient local BMP signal transduction. As VE-Cadherin interacts with ALK2 and BMPRII in a ligand-dependent manner, we propose a stabilizing function of VE-Cadherin for BMP receptor complexes in endothelial cell junctions. Interestingly, results from proximity ligation assays suggested that BMP receptors associate with VE-Cadherin in intracellular vesicles. We have previously shown that both BMPRI and BMPRII undergo clathrin-mediated endocytosis, but caveolindependent internalization was only observed for BMPRII (Hartung et al., 2006) . It has been described that VE-Cadherin is internalized via clathrin-coated pits by a p120-catenindependent mechanism (Xiao et al., 2005) . Besides, VE-Cadherin recruits caveolin-1 to endothelial cell junctions and phosphorylated caveolin-1 weakens VE-Cadherin-catenin interactions and thus regulates endothelial barrier function (Kronstein et al., 2012) .
Furthermore, a recent study demonstrated that heterozygous null Bmpr2 mutations affect Srcdependent caveolin-dependent internalization as well as phosphorylation of caveolin-1 (Prewitt et al., 2015) . These observations indicate that BMP-induced permeability may be differentially regulated by clathrin-and caveolin-dependent endocytotic mechanisms.
In this study, we show that VE-Cadherin acts as a positive regulator of endothelial BMP signal transduction and is consistent with a previously published study describing a similar role of VE-Cadherin in TGF-β signaling (Rudini et al., 2008) . It was shown that VE-Cadherin interacts with the TGF-β receptor complex and facilitates oligomerization of the complex in a ligand-dependent fashion (Rudini et al., 2008) . Moreover, using VE-Cadherin knock-out endothelial cells, the authors described that VE-Cadherin acted as a positive regulator of endothelial TGF-β signal transduction and found that proper VE-Cadherin clustering was needed for efficient signaling. These observations suggest that VE-Cadherin physically associates with receptors of the TGF-β family to stabilize their oligomerization and increase downstream signaling. This stands in contrast to the VE-Cadherin-mediated inhibition of VEGF-VEGFR2 signal transduction in confluent endothelial cells. It has been shown that VEGFR2 was dephosphorylated and its internalization was strongly reduced upon association with VE- Cadherin (Lampugnani et al., 2006) . The net effect was an inhibition of cell proliferation by decreasing efficient VEGFR2 signaling. The authors proposed that this regulatory mechanism modulated the capacity for cells to proliferate and survive in a densitydependent manner, thereby controlling contact inhibition of growth in vitro. In combination with the findings that TGF-β-induced inhibition of cell migration and proliferation was enhanced in the presence of VE-Cadherin (Rudini et al., 2008) , these observations strongly support the idea that VE-Cadherin modulates growth factor receptor signaling in favor of vessel stability. However, the herein described BMP6-induced hyperpermeability and the positive effects of VE-Cadherin on BMP signaling in vitro seem to contradict this idea. The effects of BMP6 on endothelial cells are less characterized compared to other BMP family members, such as BMP2 and BMP9. Dose-dependent binding of distinct BMP ligands cause recruitment and a unique mode of oligomerization of specific BMP receptors, which is crucial for the induction of individual downstream signaling pathways and a hallmark of this signal transduction pathway (Ehrlich et al., 2012) . It has been reported that BMP6 activates endothelial cells by induction of cell migration and tube formation (Valdimarsdottir et al., 2002) . These findings are in line with our results showing a BMP6-induced activation with respect to HUVEC permeability. However, BMP9 has been reported to inhibit basic fibroblast growth factor (bFGF-)-induced proliferation and migration of endothelial cells (Scharpfenecker et al., 2007) , indicating ligand-dependent outcomes. Similar phenomena were observed upon TGF-β stimulation in several studies. It has been shown that upon TGF-β inhibition by overexpression of soluble Endoglin, mouse retinal permeability was increased (Walshe et al., 2009) In the present study, we demonstrate that BMP6 induces endothelial cell permeability in vitro and provide mechanistic insight that BMP signaling remodels AJ architecture by promoting internalization and modification of VE-Cadherin. Our study suggests that endothelial BMP signaling is modulated by VE-Cadherin and controls barrier function (Fig. 6) . Further studies should pave the way for novel therapies in the context of acute inflammation, atherosclerosis, metastasis and multiple other pathologies associated with increased vascular permeability.
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Materials and Methods
Reagents and antibodies
All chemicals were purchased from Sigma-Aldrich, unless otherwise indicated. Production of recombinant human BMP6 was previously described (Simic et al., 2006; Vukicevic et al., 2014) . BMP6 used in the experiments has been produced under collaborative FP7 Health project Osteogrow (Grant Agreement Number 279239) by GMP manufacturing for clinical trials in patients for bone regeneration. BMP6 producer cell line is CHO DG44, suspension adapted, transduced by a Lentivirus vector with advanced safety features. Lentivirus vector was chosen for its unique features allowing highly efficient, multi-copy, stable transduction of genes into growing and stationary cells (Lentigen Corporation, Washington DC). BMP6 was purified using Heparin Sepharose, then Phenyl Sepharose, and finally subjected to C18 RP-HPLC, analysed under GMP conditions (Biochem, Germany) and found free of endotoxins and host cell proteins (SGS Vitrology, Glasgow). IMPD has been approved by national regulatory agencies in Austria and Croatia. In a standardized in vitro assay using C2C12 cells BMP6 has been compared to protein from R&D and had a similar biological potency. BMP6 was used at 10 nM, unless otherwise indicated. Recombinant human VEGF-165 was purchased from ImmunoTools and used at 2 nM. LDN-193139 was a kind gift by Paul B. Yu (Boston, USA) (Cuny et al., 2008) and Alex N. Bullock (Oxford, UK) kindly provided K02288 (Sanvitale et al., 2013) . The following antibodies were purchased from Cell Signaling Technology: rabbit anti-VE-Cadherin (D87F2), rabbit anti-phospho-Smad1/5 (Ser463/465) (41D10), rabbit anti-GAPDH (14C10), rabbit anti-phospho-Src family (Tyr416) (D49G4), rabbit anti-Src (36D10), rabbit anti-BMPR2, rabbit anti-ACVR1 (herein referred to as ALK2), mouse anti-Myc (9B11), mouse IgG1 isotype control (G3A1) and normal rabbit IgG. Furthermore, mouse anti-human VE-Cadherin (BV6, Enzo Life Sciences), goat anti-VECadherin (C-19, Santa Cruz), rabbit anti-phospho-VE-Cadherin (Tyr685, ECM Biosciences) and mouse anti-HA (HA-7, Sigma-Aldrich) were used.
Cell culture and transfections
HUVECs were a kind gift from M. Lorenz, V. Stangl and A. Pries (Berlin, Germany) and cultured on gelatine-coated tissue culture ware in M199 medium (with Earle´s salts and NaHCO3) supplemented with 20% fetal calf serum (FCS, Biochrom AG), 50 µg/ml endothelial cell growth supplement (Corning), 25 µg/ml heparin, 2 mM L-glutamine, 100 U/ml penicillin and 0.1 mg/ml streptomycin (herein referred to as HUVEC growth media) at 37°C and 5% CO2. HUVECs were used between passage two to five from isolation. Unless indicated otherwise, HUVECs were starved for six hours prior to stimulation in M199 medium (with Earle´s salts and NaHCO3) supplemented with 2 mM L-glutamine and 100 U/ml penicillin and 0.1 mg/ml streptomycin (herein referred to as HUVEC starvation media).
Pharmacological inhibitors (LDN-193189, K02288 or PP2) were added 60 minutes prior to stimulation. Equal volumes of dimethylsulfoxide (DMSO) were used to treat control cells.
For gene silencing, 40 nM of commercially available siRNA against ALK2 (herein referred to as si-ALK2), c-Src (herein referred to as si-SRC) and VE-Cadherin (herein referred to as si-CDH5) (ON-TARGETplus SMARTpool, GE Healthcare) was transfected in HUVECs using Lipofectamine2000 (LifeTechnologies) according to manufacturer´s instructions. ONTARGETplus non-targeting siRNA (herein referred to as si-scr, GE Healthcare) was used as a control.
HEK293T cells (American Type Culture Collection) were cultured and transfected as previously described (Hiepen et al., 2014) .
Expression plasmids
The full length coding sequence of human VE-Cadherin was amplified from HUVEC cDNA and cloned into pcDNA3.1 mammalian expression vector using TOPO-TA cloning (Life Technologies) according to manufacturer´s instructions. The plasmids encoding BMPRII-HA and BMPRII-Myc were previously described (Gilboa et al., 2000) . C-terminally HA-tagged human ALK2 (ALK2-HA) expression plasmid was kindly provided by K. Miyazono (Tokyo, Japan). Full-length c-Src expression plasmid was kindly provided by R. Lefkowitz (Durham, USA) and is described elsewhere (Luttrell et al., 1999) . All plasmids were verified by DNA sequencing.
RNA extraction and qRT-PCR
HUVEC total RNA was isolated as previously described (Bhushan et al., 2013) . RT-PCR was performed using SYBR Green Mix and the StepOne Plus Real-Time PCR System (Applied Biosystems). The following human-specific primer sets were used: ID1 (forward: 5'-GCTGCTCTACGACATGAACG-3', reverse: 5'-CCAACTGAAGGTCCCTGATG-3'),
CDH5
(forward: 5'-CAGCCCAAAGTGTGTGAGAA-3', reverse: 5'-CGGTCAAACTGCCCATACTT-3') and GAPDH (forward: 5'-GAAGGTGAAGGTCGGAGTC-3', reverse: 5'-GAAGATGGTGATGGGATTTC-3'). The
ΔΔCt method was used to quantify mRNA expression relative to GAPDH.
Journal of Cell Science • Advance article
Immunoprecipitation and Western Blot analysis
Immunoprecipitation of endogenous proteins from HUVECs was performed using TNE lysis buffer freshly supplemented with 0.5% Triton X-100, 1 mM phenylmethanesulfonylfluoride (PMSF, Carl Roth GmbH), 20 mM sodium pyrophosphate (NaPPi), 50 mM sodium fluoride (NaF), 300 µM freshly prepared sodium pervanadate and 1x Complete EDTA-free protease inhibitor cocktail (Roche). Immunoprecipitation of overexpressed proteins from HEK293T cells was performed using a modified radio-immunoprecipitation assay buffer freshly supplemented with inhibitors as described above. Following lysis, lysates were centrifuged at 4°C for 20 minutes at 16 000g and pre-cleared at 4°C for 30 minutes with recombinant protein A-Agarose beads (Thermo Scientific). Afterwards, aliquots were set aside for direct blot analysis (total cell lysates, TCLs) and aliquots for immunoprecipitation (IP) were incubated at 4°C for two hours or overnight with indicated antibodies. Control samples were either incubated with isotype control antibodies or recombinant protein A-Sepharose beads (GE Healthcare). Immunocomplexes were precipitated at 4°C for two hours with recombinant protein A-Sepharose beads (GE Healthcare) and subsequently washed three to five times with fresh lysis buffer including inhibitors. Proteins were eluted with 2x Laemmli sample buffer and boiled for ten minutes at 95°C.
All protein lysates were blotted and analyzed as previously described (Hiepen et al., 2014) .
Quantification of signal intensities was performed using Bio1D software (Vilber Lourmat) or Image Studio Lite software (LI-COR Biosciences) and normalized to loading control/IP TCL and untreated control samples.
Immunofluorescence microscopy
HUVECs were seeded at 200 000 cells/cm² in HUVEC growth media in µ-Slide 8-Well (ibidi) dishes 24 hours prior to the experiment. After four hours of serum starvation in HUVEC starvation media containing 1% FCS, cells were stimulated with indicated growth factors at 37°C for four or 24 hours. Subsequently, cells were fixed, quenched and permeabilized with 0.3% Triton X-100. After blocking, cells were incubated with indicated primary antibodies, followed by detection using AlexaFluor-coupled secondary antibodies (Life Technologies). Nuclei were counterstained using 4',6-diamidin-2-phenylindole (DAPI, Carl Roth GmbH). Images were taken with a CoolSnap-HQ2 CCD-camera (Roper Scientific) mounted to an inverted epifluorescence Axiovert 200M microscope (Carl Zeiss) and analyzed with Axiovision software (Carl Zeiss) and Corel DRAW X4 software (Corel).
Cell surface biotinylation
Cell surface biotinylation protocol has been described by Gabriel et al. (Gabriel et al., 2009 ).
In brief, HUVECs were seeded at 20 000 cells/cm² in HUVEC growth media 48 hours prior to the experiment, serum-starved in HUVEC starvation media containing 2% FCS for six hours at 37°C. Subsequently, cells were either stimulated with indicated growth factors for 60 minutes at 37°C or left at 4°C for total cell surface control samples. Biotinylation using cellimpermeable sulfosuccinimidyl-6-(biotin-amido)hexanoate (EZ-Link Sulfo-NHS-SS-Biotin, Thermo Scientific) and subsequent processing was performed as previously described (Gabriel et al., 2009 ).
Internalization assay
Internalization of VE-Cadherin was measured as previously described (Xiao et al., 2003b) . In brief, HUVECs were seeded at 50 000 cells/cm² (sparse) or 200 000 cells/cm² (confluent) in HUVEC growth media in µ-Slide 8-well (ibidi) dishes 24 hours prior to the experiment. After serum starvation, cell surface VE-Cadherin was labeled at 4°C with extracellular VECadherin domain targeting antibody BV6 for 60 minutes, rinsed with ice-cold PBS and stimulated with recombinant growth factors at 37°C. Subsequently, cells were subjected to a mild acid wash and internalized VE-Cadherin was visualized using immunofluorescence microscopy as described above. Internalized VE-Cadherin vesicles from at least ten images per experimental condition were quantified using BlobFinder image analysis software as previously described (Allalou and Wahlby, 2009). The results were normalized to untreated control cells.
In situ proximity ligation assay
HUVECs were seeded at 200 000 cells/cm² in HUVEC growth media in Nunc Lab-Tec II 16-well glass chamber slides (Thermo Scientific). Cells were serum-starved for two hours in HUVEC starvation media, followed by stimulation with indicated growth factors for 60 minutes. Subsequently, in situ proximity ligation was performed using Duolink in situ proximity ligation (Sigma-Aldrich) as previously described (Thymiakou and Episkopou, 2011) . The number of heteromers was quantified using BlobFinder image analysis software as previously described (Allalou and Wahlby, 2009) . At least 15-20 images per experimental condition were quantified and normalized to untreated control cells.
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Transendothelial solute permeability HUVEC monolayer solute permeability was determined using an in vitro vascular permeability 96-well assay kit (Merck Millipore) according to manufacturer´s instructions.
HUVECs were stimulated with indicated growth factors for 24 hours and monolayer solute permeability was determined by addition of a high molecular weight FITC-Dextran and subsequent measurement of fluorescence intensity using a Mithras microplate reader (Berthold Technologies). Fluorescence intensity was measured in duplicates per condition and normalized to untreated control cells.
Transendothelial electrical resistance
HUVECs were seeded at 200 000 cells/cm² in HUVEC growth media on fibronectin/collagencoated Costar 24-well transwell-inserts (0.4µm polyester membrane, Corning) 72 hours prior to the experiment. Subsequently, cells were serum-starved for four hours in HUVEC starvation media containing 2% FCS and stimulated with indicated growth factors. TEER was measured at indicated time points using a Millicell ERS-2 Voltohmmeter (Merck Millipore).
Afterwards, blank TEER values, measured in transwell-inserts without cells, were subtracted, resistance per cm² was calculated and normalized to untreated control cells at the start of stimulation (0h).
VE-Cadherin declustering
Declustering of VE-Cadherin was performed as previously described (Rudini et al., 2008) .
Statistical analysis
Statistical analysis was performed by unpaired Student´s t-test or variance analysis using
SigmaPlot software (Systat Software). p < 0.05 was considered statistically significant. 
